Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Randomized, Placebo-controlled, Open-label, Three Period Crossover Study to Investigate the Effect of Darolutamide and Enzalutamide on Cerebral Blood Flow in Healthy Male Volunteers

Next Previous
Trial Profile

A Phase I, Randomized, Placebo-controlled, Open-label, Three Period Crossover Study to Investigate the Effect of Darolutamide and Enzalutamide on Cerebral Blood Flow in Healthy Male Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 02 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Darolutamide (Primary) ; Enzalutamide (Primary)
  • Indications Bladder cancer; Breast cancer; Endometrial cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Salivary gland cancer
  • Focus Pharmacodynamics
  • Sponsors Bayer

Most Recent Events

  • 27 Apr 2023 Primary endpoint (Change in grey-matter cerebral blood flow of darolutamide as compared to placebo) has not been met, according to a results published in the Targeted Oncology.
  • 27 Apr 2023 Primary endpoint (Change in grey-matter cerebral blood flow of enzalutamide as compared to darolutamide) has been met, according to a results published in the Targeted Oncology.
  • 27 Apr 2023 Primary endpoint (Change in grey-matter cerebral blood flow of enzalutamide as compared to placebo) has been met, according to a results published in the Targeted Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top